Lexicon Pharmaceuticals stock faces a Q2 loss as trials advance

Published on 10/07/2026 at 05:30 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Lexicon Pharmaceuticals stock posted a USD 31.8 million net loss in Q2 2026, versus USD 3.3 million profit a year earlier. Revenue fell to USD 0.7 million.

LXRX, US5288723027, Illustration mit AI erstellt.

Lexicon Pharmaceuticals (ISIN US5288723027) reported a USD 31.8 million net loss for Q2 2026, compared with USD 3.3 million net income in Q2 2025. The latest market quote leaves the stock at USD 1.750 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, while the company advances two late-stage sotagliflozin programs.

Quarterly loss reflects trial spending

According to Benzinga, total revenue for the quarter ended June 30, 2026 was USD 0.7 million, down from USD 28.9 million in the same quarter of 2025. That 97.6 percent decline reflected the absence of the prior year's USD 27.5 million licensing revenue, rather than a direct comparison of recurring product sales.

Research and development expense reached USD 17.4 million in Q2 2026, compared with USD 15.7 million a year earlier, while selling, general, and administrative expense rose to USD 9.8 million from USD 9.4 million. The spending pattern puts clinical execution ahead of near-term revenue growth in the current investment case.

SONATA-HCM sets the next milestone

Benzinga reported that Lexicon completed enrollment in the Phase 3 SONATA-HCM study of sotagliflozin and expects top-line data in Q1 2027. Management also said a resubmission of the Zynquista new drug application could occur in Q4 2026, making regulatory execution the nearer checkpoint for the pipeline.

Liquidity provides a measurable counterweight to the quarterly loss. Lexicon reported USD 190.6 million in cash, cash equivalents, and short-term investments as of June 30, 2026, compared with USD 125.2 million at December 31, 2025, while a USD 100 million Hercules Capital facility expanded financing flexibility.

Analysts see a wide valuation gap

According to MarketBeat on September 28, 2026, five analysts carried a Hold consensus, with three Buy ratings, one Hold rating, and one Sell rating. The average 12-month price target was USD 5.70, which lies 225.7 percent above the USD 1.750 Nasdaq price on October 6, 2026.

MarketBeat also reported that Cantor Fitzgerald initiated coverage on September 28, 2026 with an Overweight rating and a USD 8.00 target. The gap reflects the market's dependence on future clinical and regulatory outcomes rather than current sales momentum.

Stock remains below yearly high

Lexicon Pharmaceuticals was last at USD 1.750 on Nasdaq on October 6, 2026, up USD 0.010, or 0.57 percent, from the prior close. The session range was USD 1.720 to USD 1.780, volume reached 1,640,481 shares, and the 52-week range was USD 1.100 to USD 2.680.